• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全国队列中复发型多发性硬化症患者疾病进展的临床预测因素

Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort.

作者信息

Alroughani R A, Akhtar S, Ahmed S F, Al-Hashel J Y

机构信息

a Division of Neurology , Amiri Hospital, Sharq , Kuwait.

b Neurology Clinic, Dasman Diabetes Institute , Dasman , Kuwait.

出版信息

Int J Neurosci. 2015;125(11):831-7. doi: 10.3109/00207454.2014.976641. Epub 2014 Nov 11.

DOI:10.3109/00207454.2014.976641
PMID:25329929
Abstract

BACKGROUND

Predicting disease progression over time is challenging despite the available literature data.

AIM

To assess whether baseline clinical variables of MS patients would predict the conversion to progressive phase of the disease.

MATERIALS & METHODS: Utilizing the national MS registry, patients who had relapsing onsets and had confirmed EDSS score at baseline and follow-up visits were included. Primary progressive MS and CIS patients were excluded. Clinical variables (gender, age at onset, disease duration, number of relapses, EDSS score) were collected. The end point was conversion to secondary progressive MS. Chi Square and multivariable logistic regression were used to determine the influence of clinical variables on disease progression.

RESULTS

Data of 803 MS patients with relapsing onset were analyzed. Eighty five (10.6%) patients reached the end point. The risk of disease progression was significantly higher in men (p=0.015), in patients who developed MS≥40 years of age (p=0.041) and who had ≥3 relapses during their disease course (p<0.001). Spinal cord presentation at onset was predictive of progression (aOR=2.01; p=0.06) while optic neuritis at onset was associated with lower risk of progression (aOR=0.30; p=0.03). EDSS score at first visit did not influence disease progression when tested at 2 different cutoffs (EDSS<4 vs. ≥4 and EDSS<6 vs. ≥6) using multivariable logistic regression analysis (p=0.960 and p=0.866), respectively.

CONCLUSION

Men and patients who presented at age 40 yeas or beyond had increased risk of MS progression. Spinal cord symptoms at onset and 3 or more relapses were predictive of progression.

摘要

背景

尽管有现有文献数据,但预测疾病随时间的进展仍具有挑战性。

目的

评估多发性硬化症(MS)患者的基线临床变量是否能预测疾病向进展期的转变。

材料与方法

利用国家MS登记处的数据,纳入复发型起病且在基线和随访时确诊有扩展残疾状态量表(EDSS)评分的患者。原发性进展型MS和临床孤立综合征(CIS)患者被排除。收集临床变量(性别、发病年龄、病程、复发次数、EDSS评分)。终点是转变为继发进展型MS。采用卡方检验和多变量逻辑回归分析来确定临床变量对疾病进展情况的影响。

结果

对803例复发型起病的MS患者的数据进行了分析。八十五例(10.6%)患者达到终点。男性(p = 0.015)、发病年龄≥40岁的患者(p = 0.041)以及病程中复发≥3次的患者(p < 0.001)疾病进展的风险显著更高。起病时脊髓受累表现可预测疾病进展(校正比值比[aOR]=2.01;p = 0.06),而起病时视神经炎则与较低的疾病进展风险相关(aOR = 0.30;p = 0.03)。使用多变量逻辑回归分析在2个不同的临界值(EDSS < 4与≥4以及EDSS < 6与≥6)下进行检测时,首次就诊时的EDSS评分对疾病进展无影响(p分别为0.960和0.866)。

结论

男性以及40岁及以上起病的患者MS进展风险增加。起病时的脊髓症状以及3次或更多次复发可预测疾病进展。

相似文献

1
Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort.全国队列中复发型多发性硬化症患者疾病进展的临床预测因素
Int J Neurosci. 2015;125(11):831-7. doi: 10.3109/00207454.2014.976641. Epub 2014 Nov 11.
2
Predictive value of clinical characteristics for 'benign' multiple sclerosis.“良性”多发性硬化症临床特征的预测价值
Eur J Neurol. 2007 Aug;14(8):885-9. doi: 10.1111/j.1468-1331.2007.01810.x.
3
Secondary progressive multiple sclerosis - clinical course and potential predictive factors.继发进展型多发性硬化症——临床病程及潜在预测因素
Neurol Neurochir Pol. 2008 Jan-Feb;42(1):6-11.
4
Natural history of multiple sclerosis: a unifying concept.多发性硬化症的自然史:一个统一的概念。
Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16.
5
The clinical course of multiple sclerosis patients in Hong Kong.香港多发性硬化症患者的临床病程。
J Neurol Sci. 2008 May 15;268(1-2):78-82. doi: 10.1016/j.jns.2007.11.006. Epub 2008 Feb 20.
6
Longitudinal follow-up of "benign" multiple sclerosis at 20 years.“良性”多发性硬化症20年的纵向随访
Neurology. 2007 Feb 13;68(7):496-500. doi: 10.1212/01.wnl.0000253185.03943.66.
7
Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.预测复发缓解型多发性硬化症的严重程度:横断面和短期随访 MRI 数据的贡献。
Mult Scler. 2011 Jun;17(6):695-701. doi: 10.1177/1352458510394454. Epub 2011 Jan 12.
8
Predictors of relapse rate in MS clinical trials.多发性硬化症临床试验中复发率的预测因素。
Neurology. 2005 Dec 13;65(11):1769-73. doi: 10.1212/01.wnl.0000187122.71735.1f.
9
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.迟发性和早发性复发缓解型多发性硬化症:来自回顾性长期随访研究的证据。
Eur J Neurol. 2018 Dec;25(12):1425-1431. doi: 10.1111/ene.13745. Epub 2018 Aug 3.
10
Clinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.科威特多发性硬化症的临床特征:来自 Amiri 医院新多发性硬化症登记处的数据。
Int J Neurosci. 2012 Feb;122(2):82-7. doi: 10.3109/00207454.2011.630543. Epub 2011 Nov 15.

引用本文的文献

1
Predictive factors for the progression of multiple sclerosis: a meta-analysis.多发性硬化症进展的预测因素:一项荟萃分析。
Neurol Sci. 2025 May 13. doi: 10.1007/s10072-025-08142-6.
2
Obesity Control and Supplementary Nutraceuticals as Cofactors of Brain Plasticity in Multiple Sclerosis Populations.肥胖症控制与补充性营养保健品作为多发性硬化症患者大脑可塑性的协同因子。
Int J Mol Sci. 2024 Oct 10;25(20):10909. doi: 10.3390/ijms252010909.
3
Circular RNA in Multiple Sclerosis: Pathogenicity and Potential Biomarker Development: A Systematic Review.
多发性硬化症中的环状RNA:致病性与潜在生物标志物开发:一项系统综述
Epigenet Insights. 2023 Nov 29;16:25168657231213195. doi: 10.1177/25168657231213195. eCollection 2023.
4
Targeting Fibronectin to Overcome Remyelination Failure in Multiple Sclerosis: The Need for Brain- and Lesion-Targeted Drug Delivery.靶向纤维连接蛋白克服多发性硬化症中的髓鞘再生失败:脑内和病灶靶向药物递送的必要性。
Int J Mol Sci. 2022 Jul 29;23(15):8418. doi: 10.3390/ijms23158418.
5
Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis.性别对多发性硬化症疾病活动和残疾累积的定量影响。
J Neurol Neurosurg Psychiatry. 2022 Jul;93(7):716-722. doi: 10.1136/jnnp-2022-328994. Epub 2022 Apr 7.
6
Determinants of disability development in patients with multiple sclerosis.多发性硬化症患者残疾发展的决定因素。
Arq Neuropsiquiatr. 2021 Jun;79(6):489-496. doi: 10.1590/0004-282X-ANP-2020-0338.
7
The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.芬戈莫德治疗复发型多发性硬化症患者的疗效与安全性:一项荟萃分析。
Br J Clin Pharmacol. 2020 Apr;86(4):637-645. doi: 10.1111/bcp.14198. Epub 2020 Feb 8.
8
The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials.那他珠单抗与芬戈莫德治疗复发缓解型多发性硬化症患者的疗效:一项系统评价、随机安慰剂对照试验的间接证据及观察性头对头试验的荟萃分析
PLoS One. 2016 Sep 29;11(9):e0163296. doi: 10.1371/journal.pone.0163296. eCollection 2016.